Product description

Trastuzumab biosimilar, recombinant humanized IgG1 monoclonal antibody against the human epidermal growth factor receptor 2 (HER2) that has been shown to inhibit the proliferation of HER2 overexpressing cancer cells. Indications: HER2 positive breast cancer (early and metastatic forms), metastatic adenocarcinoma of the stomach or gastro-esophageal junction with HER2 overexpression. Currently >31 000 patients treated, >371 000 vials sold, marketed in 18 countries.
Read more

More products from BIOCAD

View all our products (9)

Products from other suppliers